Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council of Australia (1173958)
National Health and Medical Research Council of Australia (1132519)
National Health and Medical Research Council of Australia (1159593)
Naito Foundation
Leukemia Foundation of Australia (SERP)
- License Information
-
More Information
Article History
Received: 5 June 2020
Accepted: 28 July 2020
First Online: 12 August 2020
Consent for publication
: Not applicable
: Mark J. Smyth has research agreements with Bristol Myers Squibb and Tizona Therapeutics and serves on the Scientific Advisory Board of Tizona Therapeutics and Compass Therapeutics.
